To highlight ten distinguishing features of acute respiratory failure (ARF) in immunocompromised patients that have important diagnostic, therapeutic, prognostic, and ethical implications.
Approach:
Increased incidence of ARF and ARDS: Immunocompromised patients account for approximately 20% of ARDS cases despite representing only about 7% of the US population.
Distinct biological heterogeneity and phenotypes: ARF is biologically heterogeneous, with potential distinct subphenotypes in immunocompromised patients that require specific phenotyping frameworks.
Broader etiologic spectrum: The etiologic spectrum of ARF is broader in immunocompromised patients, including opportunistic infections and drug-induced lung injury.
Importance of establishing a diagnosis: Undetermined etiology in ARF is associated with higher mortality, emphasizing the need for thorough diagnostic approaches.
Diagnostic procedures require careful risk–benefit assessment: Bronchoscopy may worsen respiratory status in immunocompromised patients, necessitating careful consideration.
Mortality remains higher despite progress: Crude mortality for ARDS in immunocompromised patients remains at 50-60%, exceeding that of immunocompetent patients.
Non-invasive respiratory support requires close monitoring: Noninvasive ventilation strategies are common but predicting their failure is challenging in this population.
ECMO demands exceptional patient selection: The role of VV-ECMO in immunocompromised patients is controversial, with poor outcomes in certain subgroups.
Key Findings:
Immunocompromised patients account for approximately 20% of ARDS cases despite representing only about 7% of the US population.
ARF is biologically heterogeneous, with potential distinct subphenotypes in immunocompromised patients that require specific phenotyping frameworks.
The etiologic spectrum of ARF is broader in immunocompromised patients, including opportunistic infections and drug-induced lung injury.
Undetermined etiology in ARF is associated with higher mortality, emphasizing the need for thorough diagnostic approaches.
Bronchoscopy may worsen respiratory status in immunocompromised patients, necessitating careful consideration.
Crude mortality for ARDS in immunocompromised patients remains at 50-60%, exceeding that of immunocompetent patients.
Noninvasive ventilation strategies are common but predicting their failure is challenging in this population.
The role of VV-ECMO in immunocompromised patients is controversial, with poor outcomes in certain subgroups.
Interpretation:
The article highlights the unique challenges and considerations in managing ARF in immunocompromised patients.
Limitations:
The findings may not be generalizable to all immunocompromised patients due to variability in underlying conditions.
Lack of validated prediction tools for noninvasive respiratory support in this population.
Conclusion:
The management of ARF in immunocompromised patients requires a nuanced understanding of their unique risks and treatment responses.
